Marco Cavaleri | Head of Public Health Threats
European Medicines Agency

Day 1 (20th October) @ 09:00

The Technology Revolution: Agility for the Wave of Next Generation Vaccines

• What new vaccines are on the horizon and what are our key scientific leaders championing?  
• How close are we to precision immunology? What is the roadmap for platform vaccines in oncology, autoimmune disorders, and infectious diseases? 
• What are the key performance and logistical benefits of advanced platforms (e.g. RNA) compared to traditional vaccine approaches? 
• Which platform technologies are most likely to cut response timelines and deliver on the 100-day mission? 
• How are regulatory agencies adapting their approval pathways to novel vaccines, new antigens and using AI in vaccine R&D and manufacturing?  

Marco Cavaleri, Head of Public Health Threats, European Medicines Agency

Charlotte Vernhes, Director Scientific and Medical Affairs, Vaccines Europe

×

Charlotte Vernhes / The Technology Revolution: Agility for the Wave of Next Generation Vaccines

Charlotte Vernhes, Director Scientific and Medical Affairs,
Vaccines Europe

Charlotte Vernhes is a bioengineer with 15 years of experience in vaccine research and development, spanning immunogenicity assessment, translational science, innovation management and public-private partnerships. Charlotte has played a pivotal role in European initiatives on RSV, where she focused ...

CloseMore

Jerome Kim, Director General, IVI

Jean-Francois Toussaint, Global Head of Research and Development Vaccines, Sanofi

Moderator: Peter Marks, SVP Molecule Discovery and Head of Infectious Diseases, Eli Lilly

×

Peter Marks / The Technology Revolution: Agility for the Wave of Next Generation Vaccines

Peter Marks, SVP Molecule Discovery and Head of Infectious Diseases,
Eli Lilly

Peter Marks received his graduate degree in cell and molecular biology and his medical degree at New York University and completed Internal Medicine residency and Hematology/Medical Oncology training at Brigham and Women’s Hospital in Boston. He has worked in academic settings teaching and caring...

CloseMore

Lucy Chappell, Chief Scientific Adviser, UK Department of Health and Social Care

Robert Walker, Executive Vice President, Head of R&D, Novavax

×

Robert Walker / The Technology Revolution: Agility for the Wave of Next Generation Vaccines

Robert Walker, Executive Vice President, Head of R&D,
Novavax

Dr. Walker is Executive Vice President and Head of Research & Development and previously served as Novavax’s Chief Medical Officer. A specialist in internal medicine and pulmonary and critical care medicine, Dr. Walker has more than 30 years of experience in drug and vaccine development within...

CloseMore